Preventing Microalbuminuria in Type 2 Diabetes (VARIETY)
A Prospective, Randomized, Probe Trial to Evaluate Whether, at Comparable Blood Pressure Control, Combined Therapy With the ACEI Benazepril and the ARB Valsartan, Reduces the Incidence of Microalbuminuria More Effectively Than BEN or VAL Alone in Hypertensive Patients With Type 2 Diabetes and High-normal Albuminuria
Sponsor: Agenzia Italiana del Farmaco
A PHASE3 clinical study on Diabetes, this trial is completed. The trial is conducted by Agenzia Italiana del Farmaco and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agenzia Italiana del Farmaco
- Mario Negri Institute for Pharmacological Research
For direct contact, visit the study record on ClinicalTrials.gov .